MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation

Carcinogenesis

Volumn 36, Issue 3, 2014, Pages 338-345

  Toshinaga Suto, ^a   Yokobori, Takehiko ^a   Yajima, Reina ^a   Morita, Hiroki ^a   Fujii, Takaaki ^a   Yamaguchi, Satoru ^a   Altan, Bolag ^a   Tsutsumi, Souichi ^a   Asao, Takayuki ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; EGFR PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MIRN7 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COLORECTAL SURGERY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84924444993     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu242     Document Type: Article

References (21)

1. Jemal, A. et al. (2011) Global cancer statistics. CA. Cancer J. Clin., 61, 69-90.
2. Center, M.M. et al. (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol. Biomarkers Prev., 18, 1688-1694.
3. Hurwitz, H. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350, 2335-2342.
4. Saltz, L.B. et al. (2008) Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J. Clin. Oncol., 26, 2013-2019.
5. Jonker, D.J. et al. (2007) Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med., 357, 2040-2048.
6. Van Cutsem, E. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 360, 1408-1417.
7. Spano, J.P. et al. (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol., 16, 102-108.
8. Bianco, R. et al. (2007) Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol., 39, 1416-1431.
9. Prigent, S.A. et al. (1992) The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res., 4, 1-24.
10. Salomon, D.S. et al. (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183-232.
11. Saltz, L.B. et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol., 22, 1201-1208.
12. Cunningham, D. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 351, 337-345.
13. Hanna, N. et al. (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol., 24, 5253-5258.
14. Misale,S. et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486, 532-536.
15. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
16. Rai, K. et al. (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor- resistance in lung cancer cells. Mol. Cancer Ther., 10, 1720-1727.
17. Atkins, D. et al. (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem., 52, 893-901.
18. Webster, R.J. et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem., 284, 5731-5741.
19. Razis, E. et al. (2014) EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J. Cancer Res. Clin. Oncol., 140, 737-748.
20. Dhomen, N. et al. (2007) New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev., 17, 31-39.
21. Chou, Y.T. et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res., 70, 8822-8831.